In conclusion, our results suggest that bladder cancer cells and xenografts with KDM6A and SWI/SNF family member mutations can benefit from EZH2 inhibition that increases NK cell activity leading to reduction in cells with pluripotency potential (Fig. 6e). The gene discussed is EZH2; the disease is urinary bladder carcinoma.